Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm, Open-label, Multicenter, Dose-escalation Clinical Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of KIV-318 Injection in Patients With Relapsed/Refractory Multiple Myeloma.

NCT07726160 is registered in ClinicalTrials.gov with Institute of Hematology & Blood Diseases Hospital, China as lead sponsor.

NCT NCT07726160
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07726160 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm, Open-label, Multicenter, Dose-escalation Clinical Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of KIV-318 Injection in Patients With Relapsed/Refractory Multiple Myeloma.
Lead sponsor
Institute of Hematology & Blood Diseases Hospital, China
Phase
Phase 1
Overall status
Not yet recruiting
Start date
July 20, 2026
Completion date
July 1, 2029
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapse and/or refractory multiple myeloma